Glasgow diagnostics spinout Microplate Dx has closed a £2.5 million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid....
A biotech advancing small molecule antibiotics through preclinical studies has closed its seed financing round of €1.2million ($1.3million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF).
The report compiles several of the key factors that are driving the growth of antimicrobial resistance, highlighting the pharmaceutical industry as a key economic sector driving the issue.
GSK announces it initiated Phase III trials for gepotidacin, the first in a new class of antibiotics, as an potential treatment for urinary tract infection.
EMA assembles pharmaceutical developers to strengthen antimicrobial pipelines while, in the meantime, a study found the world’s rivers dangerously contaminated.
A skin patch designed to deliver antibiotics directly into the bloodstream could prevent the development of antimicrobial resistance in gut bacteria, say scientists in Ireland.
Fraunhofer is “redoubling” its efforts to develop new antibiotics and transfer research into clinical trials through a project available to external partners for development.
A researcher at South Africa’s Stellenbosch University (SU) says biosurfactants made by bugs in municipal wastewater could help drug makers develop new antibiotics.
Regulators in Europe, Japan and the US say they have aligned clinical data requirements for new antibiotics to encourage industry to develop drugs for infections caused by resistant bacteria.
IFPMA launches Alliance to track drug firms' progress in the fight against ‘superbugs'.
Drug manufacturers, retail pharmacies and regulators have a role to play in curbing antimicrobial resistance say campaigners urging industry to ensure their API suppliers are not part of the problem.
Indian regulators want manufacturers to discourage pharmacists from selling antibiotics to patients without prescriptions as part of an effort to curb the spread of superbugs.
A “quality mark” for firms that source from green API suppliers would add patient choice element to fight against antimicrobial resistance according to DSM Sinochem Pharmaceuticals.
Drug companies need to me more open about their API suppliers to help fight the spread of antimicrobial resistance (AMR) according to DSM Sinochem Pharmaceuticals.
An issue at a GSK API manufacturing site will limit supplies of the superbug busting antibiotic Avycaz for the next six months according to drug manufacturer Allergan.
Scientists at AstraZeneca’s former R&D site in Alderley Park will play a key role in researching antibiotics and the spread of resistance under an initiative launched by US President Barack Obama.
Industry backing for a G7 plan to preserve antibiotics is at odds with current marketing practices says an NGO calling for a clamp down on campaigns that promote overuse.
Bacterial resistance to ciproflaxin is spreading according to the European CDC which wants the drug industry to invest in development of alternatives to the "last resort" antibiotic.
Under new legislation, the FDA and NIH will receive discretionary funding to combat antibiotic resistant bacteria and advance prevision medicine initiatives.
API firms that invest in waste management find it hard to compete with those that pollute according to DSM Sinochem, which wants environmental criteria included in GMP standards for environmental and business reasons.
Antibiotic API makers have an obligation to ensure their activities do not spread resistance says a group that welcomed DSM-Sinochem’s commitment to environmentally-friendly production.
A group calling for GMP assessments to consider the environmental impact of API production says pollution generated by suppliers in China is furthering the spread of resistant superbugs.
Drug industry execs at the World Economic Forum in Davos, Switzerland were told they are no longer best placed to develop antibiotics by a panel who said Governments should lead efforts to create these vital new drugs.
Cubist will give Merck & Co leadership of the antibiotics sector according to one analyst who says renewed interest expressed by GSK, Roche and Sanofi has not produced any Ph III candidates.
A single-dose of an investigational MRSA drug could be equivalent to a ten-day course of antibiotics due to the application of PK-PD principles in its design and optimization, The Medicines Company says.
Marine bacteria may yield the next generation of MRSA fighting drugs according to a team that used a peptide from a Pacific Ocean bug to render the hospital superbug less lethal.
Roche could restart its antibiotic development activities if a superbug busting drug candidate being developed by new partner Polyphor fulfils its early clinical promise.
US scientists have claimed that ‘bacterial autopsies’ could accelerate the discovery of new antibiotics in an announcement made just days after the US CDC warned of a potential “post-antibiotic era” and called for renewed development efforts.
PPD will work with J&J’s Belgian subsidiary, Janssen Pharmaceutica, on drugs for bowel, skin and lung diseases in a $330m in a deal announced yesterday.
MRSA could be treated through a combination of an antimicrobial drug, a peptide and light, according to researchers who have hailed the treatment as a “magic bullet”.
While the media calls out for new antibacterials, the majority of
large pharmaceutical companies seem disinterested in investing in
new treatments, leaving smaller biotechs to pick up the gauntlet.
Scientists have today unveiled a technique for tipping the balance
in favour of antibiotics in their fight against increasingly
drug-resistant 'superbugs'.
Novexel has announced it is to put forward its novel small molecule
antibiotic into Phase I clinical development representing a new
class of antibacterials to treat hospital-based infections caused
by gram positive pathogens.
Researchers have demonstrated the effectiveness of a new drug for
treating infections caused by Staphylococcus aureus bacteria
representing the first drug of its kind to be FDA approved in two
decades.
A recently published report has highlighted the use of antibiotics
in the rearing of fish could promote bacterial resistance leading
to the evolution of resistant strains of bacteria in humans as well
as the fish themselves.
Researchers, who believe they have discovered only the third
entirely new antibiotic developed in the last four decades, have
developed an antibiotic, which targets microorganisms that include
MRSA.
Arpida has announced it has successfully completed a Phase I
clinical trial with oral iclaprim in a capsule formulation. This
broad-spectrum antibiotic targets infections requiring hospital
treatment, including those caused by methicillin-resistant...
